Comment on “Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update”

Figures

• 

  Fig. 1. Scatter diagram showing the assessment of the average overall harm of a substance in relation to its average benefit assessment (category: “no/little benefit”). Two groups are already visually demarcated (lower left square: prescription drugs; upper right square: traditional drugs of abuse except of cannabis and ketamine). Assessments were performed by 101 German physicians both specialized in addiction medicine and working for a median of 15 years in the tertiary care of patients with substance-use disorders [9, 10]. Note that this assessment is not representative for countries dealing with an opioid epidemic (where the potential synergy/opioid-sparing features of gabapentanoids (GPs) or other CNS depressants might be more salient)